top of page
The latest from NuvOx
Search
NuvOx and FYR Bio Announce NCI Funding for Liquid Biopsy Collaboration Supporting NuvOx’s Phase IIb Glioblastoma Trial
Tucson, AZ – September 26, 2025 – NuvOx Therapeutics, Inc. (“NuvOx”) and FYR Bio (“FYR”) today announced a collaboration pairing NuvOx’s...
Oct 9, 2025
NuvOx Welcomes Wilson W. Cheung as An Independent Board Member
Tucson, AZ – September 26, 2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that it has appointed Mr. Wilson W. Cheung, CPA, as an...
Oct 3, 2025
NuvOx Announces Dosing of 87th Patients in Its RESTORE trial: A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Tucson, AZ – September 26, 2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that it has dosed 87 patients in its RESTORE trial: A...
Sep 29, 2025
NuvOx Announces First Patient Dosed for its EXTEND trials: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials
Tucson, AZ – June 12, 2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been dosed for its EXTEND trials :...
Jun 17, 2025
NIH Panel - Commercializing SBIR/STTR Technologies
Featuring Co-Founder and Executive Chairman Dr. Evan Unger As Panelist in Commercializing SBIR/STTR Technologies Discussion at 2025 BIO...
Jun 13, 2025
bottom of page